Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depoxythilone - Beijing Biostar Technologies

Next Previous
X
Search
Drug Profile

Depoxythilone - Beijing Biostar Technologies

Alternative Names: UTD-1; UTD-2; Utidelone; Utidelone - Beijing Biostar Technologies

Latest Information Update: 18 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Biostar Technologies; BioStar Pharmaceuticals
  • Developer Beijing Biostar Technologies; BioStar Pharmaceuticals; Henan Cancer Hospital
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Breast cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Non-small cell lung cancer
  • Phase II Colorectal cancer; Gastric cancer; HER2 negative breast cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Dec 2024 Beijing Biostar Pharmaceuticals plans a phase II trial for Solid tumours (Late stage disease, Unresectable/Inoperable, Metastatic disease, Second line therapy or greater, Monotherapy) in December 2024 (NCT06730581)
  • 03 Sep 2024 BioStar plans to submit IND application for phase II/III trial in China and the US
  • 03 Sep 2024 Biostar Pharma completes enrolment in a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second line therapy or greater) (PO, Capsule) (NCT05681000)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top